MDT-AP-3048
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 32.8
- sex
- F
- new_clusters
- S3
- umap1_2d
- -0.277421622
- umap2_2d
- -9.248277774
- umap1_3d
- -3.422232626
- umap2_3d
- -2.101615085
- umap3_3d
- 6.645211915
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.270
- CHOLESTEROL_HOMEOSTASIS+0.230
- PROTEIN_SECRETION+0.220
- PANCREAS_BETA_CELLS+0.210
- MITOTIC_SPINDLE+0.200
- G2M_CHECKPOINT+0.170
- ANDROGEN_RESPONSE+0.150
- WNT_BETA_CATENIN_SIGNALING+0.140
- UV_RESPONSE_DN+0.110
- APICAL_SURFACE+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.510
- ALLOGRAFT_REJECTION-0.440
- INTERFERON_GAMMA_RESPONSE-0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- DNA_REPAIR-0.360
- IL6_JAK_STAT3_SIGNALING-0.360
- COAGULATION-0.330
- TNFA_SIGNALING_VIA_NFKB-0.330
- INFLAMMATORY_RESPONSE-0.320
- COMPLEMENT-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518441 | — | D | 0.868 |
| 2 | MNG214 | — | — | 0.838 |
| 3 | 2e15a781-21c1-421b-9e92-6d2d414e0d14 | — | — | 0.823 |
| 4 | b98a06c6-3b43-4749-98cf-b28f4ba06845 | — | — | 0.821 |
| 5 | 74d58c33-0c42-47bc-a55b-f56835480fbe | — | — | 0.814 |
| 6 | MDT-AP-0184 | Med | Medulloblastoma | 0.811 |
| 7 | SRR8392885 | — | cohortA3 | 0.794 |
| 8 | 2c343b93-910c-4921-bc2b-f7fbfa4f1596 | — | — | 0.792 |
| 9 | 37e6146e-6fec-4160-822c-404a517610a8 | — | — | 0.789 |
| 10 | TCGA-A2-A1FV-01A-11R-A13Q-07 | — | B | 0.788 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.270 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.220 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.170 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.030 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.030 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.020 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |